ASCO-Update 2005 - Neuigkeiten vom 41. Meeting der American Society of Clinical Oncology/ASCO 2005

T. Höhler; M. Heike; M. P. Lutz; U. Graeven; T. Seufferlein

doi:10.1055/s-2005-858746

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Z Gastroenterol 2005; 43(11): 1253-1259
DOI: 10.1055/s-2005-858746

Übersicht

ASCO-Update 2005 - Neuigkeiten vom 41. Meeting der American Society of Clinical Oncology/ASCO 2005

ASCO-Update 2005 - Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005T. Höhler¹ , M. Heike² , M. P. Lutz³ , U. Graeven⁴ , T. Seufferlein⁵

¹Prosper Hospital Recklinghausen
²Medizinische Klinik Mitte, Klinikum Dortmund
³Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
⁴Krankenhaus St. Franziskus, Mönchengladbach
⁵Abt. Innere Medizin I, Universitätsklinikum Ulm

Further Information

Publication History

Publication Date:
03 November 2005 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

Zusammenfassung

Die onkologische Therapie gastrointestinaler Tumore unterliegt durch die Einführung neuer Chemotherapeutika und den zunehmenden Einsatz von „Targeted Therapies” einem raschen Wandel. Wir möchten in der folgenden Übersicht die wichtigsten neuen klinischen Studien zu Ösophagus-, Magen-, kolorektalen, Pankreas-, Leber- und Gallenwegskarzinomen vorstellen und bewerten, die auf dem diesjährigen Meeting der American Society of Clinical Oncology präsentiert wurden.

Abstract

Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review provides an overview of the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - Gallenwegskarzinom - Targeted Therapies - klinische Studien

Key words

Esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - targeted therapies - clinical trials

Literatur
(angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

1 Al-Batran S E, Stöhlmacher J, Probst S. et al . Fluorouracil, leukovorin and oxaliplatin (FLO) versus fluorouracil, leukovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer; first interim analysis of a randomsed multicenter phase II study. Proc ASCO. 2005; A 4015

PubMed Search in Google Scholar
2 Andre T, Boni C, Mounedji-Boudiaf L. et al . Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 43 2343-2351

PubMed Search in Google Scholar
3 Arkenau H, Schmoll H, Kubicka S. et al . Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc ASCO. 2005; A 3507

PubMed Search in Google Scholar
4 Barbare J C, Bouché O, Bonnetain F. et al . Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001 - 01 CHOC). Proc ASCO. 2005; A 4036

PubMed Search in Google Scholar
5 Berlin J D, Catalano P, Thomas J P. et al . 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 43 3270-3275

PubMed Search in Google Scholar
6 Boige V, Raoul J, Pignon J. et al . Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): a phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003 - 03 trial). Proc ASCO. 2005; A 4128

PubMed Search in Google Scholar
7 Bosset J F, Calais G, Mineur L. et al . Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22 921 trial. Proc ASCO. 2005; A3505

PubMed Search in Google Scholar
8 Cascinu S, Labianca R, Barone C. et al . High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen. Proc ASCO. 2005; A4023

PubMed Search in Google Scholar
9 Chua Y J, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol. 2005; 43 4532-4537

PubMed Search in Google Scholar
10 Cunningham D, Allum D, Stenning, Weeden S. for the NCRI Upper GI Clinical Studies Group .Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Finasl results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93 793 971). Proc ASCO 2005: A4001

Search in Google Scholar
11 Dank M, Zaluski J, Barone C. et al . Randomized phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc ASCO. 2005; A 61

PubMed Search in Google Scholar
12 de Gramont A, Boni C, Navarro M. et al . Oxaölipaltin/5FU/LV in the adjuvant treatment of stage II and Stage III colon cancer: Efficacy results with a mdian follow-up of 4 years. Proc ASCO. 2005; A 3501

PubMed Search in Google Scholar
13 Díaz R ubio E, Tabernero J, van Cutsem E. et al . Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proc ASCO. 2005; A3535

PubMed Search in Google Scholar
14 Doffoel M, Vetter D, Bouche O. et al . Multicenter randomized Phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. Proc ASCO. 2005; A4128

PubMed Search in Google Scholar
15 Duyster J, Lorenzen S, Kullmann F. et al . Oxaliplatin plus 5FU/folinic acid (FUIFOX Regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenterr Phase II STOMOX Trial. Proc ASCO. 2005; A 4016

PubMed Search in Google Scholar
16 Eberl T, Graeven U, Heike M. et al . ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003. Z Gastroenterol. 2003; 43 1039-1045

Thieme Connect PubMed Search in Google Scholar
17 Gebbia N, Verderame F, Di Leo R. et al . A phase II study of Oxaliplatin (O) and Gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers. Proc ASCO. 2005; A 4132

PubMed Search in Google Scholar
18 Gerard J, Bonnetain F, Conroy T. et al . Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3 - 4 rectal cancers : results of the FFCD 9203 randomized trial. Proc ASCO. 2005; A 3504

PubMed Search in Google Scholar
19 Giantonio B J, Catalano P J, Meropol N J. et al . High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO. 2005; A 2

PubMed Search in Google Scholar
20 Glover K Y, Thomas M B, Brown T D. et al . A Phase II Study of Oxaliplatin and Capecitabine (XELOX) in Patients with Unresectable Cholangiocarcinoma, including Carcinoma of the Gallbladder and Biliary Tract. Proc ASCO. 2005; A 4123

PubMed Search in Google Scholar
21 Graeven U, Heike M, Hohler T. et al . ASCO update - highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004. Z Gastroenterol. 2004; 43 1416-1424

Thieme Connect PubMed Search in Google Scholar
22 Hecht J R, Trarbach T, Jaeger E. et al . A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222 584 or placebo (CONFIRM-1). Proc ASCO. 2005; A 3

PubMed Search in Google Scholar
23 Heinemann V, Hoehler T, Seipelt G. et al . Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer. Proc ASCO. 2005; A 4030

PubMed Search in Google Scholar
24 Herrmann R, Bodoky G, Ruhstaller T. et al . Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc ASCO. 2005; A 4010

PubMed Search in Google Scholar
25 Hochster H S, Welles L, Hart L. et al . Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc ASCO. 2005; A3515

PubMed Search in Google Scholar
26 Kawashima M, Kagami Y, Oguchi M. et al . A phase II trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Proc ASCO. 2005; A 8026

PubMed Search in Google Scholar
27 Kinoshita T, Nakajima T, Ohashi Y. Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: Results of a randomized trial by national surgical adjuvant study of gastric cancer. Proc ASCO. 2005; A 4021

PubMed Search in Google Scholar
28 Kozloff M, Cohn A, Christiansen N. et al . Safety of bevacizumab (BV, Avastin™) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) - preliminary results from a larger registry in the US. Proc ASCO. 2005; A 3566

PubMed Search in Google Scholar
29 Liang H. Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in Inoperable Pancreatic Cancer: A meta-analysis. Proc ASCO. 2005; A 4110

PubMed Search in Google Scholar
30 Lin A Y, Fisher G, So S. et al . A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc ASCO. 2005; A 4223

PubMed Search in Google Scholar
31 Moiseyenko V, Ajani J A, Tjulandin S. et al . Final results of a randomized controlled phase III trial comparing docetaxel (D), combined with cisplatin (C), 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc ASCO. 2005; A 4002

PubMed Search in Google Scholar
32 Moore M J, Goldstein D, Hamm J. et al . Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc ASCO. 2005; A 1

PubMed Search in Google Scholar
33 Muro K, Najima M, Hamaguchi T. et al . Definitive chemoradiotherapy followed by salvage therapy for locoregional failure might be a standard treatment option for stages I-III esophageal squamous cell carcinoma. Proc ASCO. 2005; A 4069

PubMed Search in Google Scholar
34 Neuhaus P, Oettle H, Post S. et al . A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc ASCO. 2005; A 4013

PubMed Search in Google Scholar
35 Oettle H, Pelzer U, Stieler J. et al . Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive careversus best supportive care alone (BSC) in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc ASCO. 2005; A 4031

PubMed Search in Google Scholar
36 Park J O, Kang W K, Kim T. et al . A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC). Proc ASCO. 2005; A 4133

PubMed Search in Google Scholar
37 Riess H, Helm A, Niedergethmann M. et al . A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer. Proc ASCO. 2005; A 4009

PubMed Search in Google Scholar
38 Rowland K M, Pitot H C, Sargent D J. et al . Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Proc ASCO. 2005; A 3519

PubMed Search in Google Scholar
39 Sakamoto J, Morita S, Tsuburaya A. et al . Efficacy of adjuvant chemotherapy with oral fluorinated pyrimidines for patients with curatively resected gastric cancer. A meta-analysis of centrally randomized controlled clinical trials. Proc ASCO. 2005; A 4022

PubMed Search in Google Scholar
40 Sauer R, Becker H, Hohenberger W. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 43 1731-1740

PubMed Search in Google Scholar
41 Schalhorn A, Ludwig F, Quietzsch D. et al . Phase III Trial of Irinotecan Plus Oxalipatin (IROX) Versus Irinotecan Plus 5-FU/Folinic Acid (FOLFIRI) as First-Line Treatment of Metastatic Colorectal Cancer (CRC): The FIRE-Trial. Proc ASCO. 2005; A 3516

PubMed Search in Google Scholar
42 Shapiro J, Marshall J, Karasek P. et al . G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. Proc ASCO. 2005; A 4012

PubMed Search in Google Scholar
43 Skillings J R, Johnson D H, Miller K. et al . Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc. ASCO. 2005; A 3019

PubMed Search in Google Scholar
44 Tsavaris N, Kosmas C, Skopelitis H. et al . Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs. 2005; 43 369-375

PubMed Search in Google Scholar
45 Van Cutsem E, Labianca R, Hossfeld D. et al . PETACC 3. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc ASCO. 2005; A 8

PubMed Search in Google Scholar
46 Wolmark N, Wieand H S, Kuebler J P. et al . A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO. 2005; A 3500

PubMed Search in Google Scholar
47 Ychou M, Raoul J, Douillard J. et al. for the GI Group of the FNCLCC and the FFCD .A phase III randomized trial of LV5FU2 +CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Proc ASCO 2005: A 3502

Search in Google Scholar
48 Zhu A X, Sahani D, Norden-Zfoni A. et al . A Phase II Study of Gemcitabine, Oxaliplatin in Combination with Bevacizumab (GEMOX-B) in Patients with Hepatocellular Carcinoma. Proc ASCO. 2005; A 4120

PubMed Search in Google Scholar

Prof. Dr. Thomas Seufferlein

Universitätsklinik Ulm, Abteilung für Innere Medizin I

Robert-Koch-Straße 8

89081 Ulm

Email: Thomas.Seufferlein@uniklinik-ulm.de

Subscribe to RSS

Share / Bookmark

ASCO-Update 2005 - Neuigkeiten vom 41. Meeting der American Society of Clinical Oncology/ASCO 2005

Publication History

Zusammenfassung

Abstract

Schlüsselwörter

Key words

Literatur (angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)

Literatur
(angegeben sind jeweils die Nummern der Abstracts, die unter www.asco.org eingesehen werden können)